Ceftriaxone Treatment for Neuronal Deficits: A Histological and MEMRI Study in a Rat Model of Dementia with Lewy Bodies

Behavioural Neurology
Ying-Jui HoI-Yen Lee

Abstract

Dementia with Lewy bodies (DLB) is characterized by neuronal deficits and α-synuclein inclusions in the brain. Ceftriaxone (CEF), a β-lactam antibiotic, has been suggested as a therapeutic agent in several neurodegenerative disorders for its abilities to counteract glutamate-mediated toxicity and to block α-synuclein polymerization. By using manganese-enhanced magnetic resonance imaging (MEMRI) and immunohistochemistry, we measured the effects of CEF on neuronal activity and α-synuclein accumulation in the brain in a DLB rat model. The data showed that CEF corrected neuronal density and activity in the hippocampal CA1 area, suppressed hyperactivity in the subthalamic nucleus, and reduced α-synuclein accumulation, indicating that CEF is a potential agent in the treatment of DLB.

References

Oct 9, 1995·Brain Research·A TakedaS Okada
Oct 27, 1997·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·Y J Lin, A P Koretsky
May 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·M G SpillantiniM Goedert
Oct 15, 1998·The New England Journal of Medicine·P LimousinA L Benabid
Jun 22, 2000·Neurobiology of Disease·B C CampbellC A McLean
Jun 15, 2001·The Journal of Comparative Neurology·H A Cameron, R D McKay
Aug 7, 2001·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·L CapusS Z Marsala
Dec 31, 2002·Brain Research. Brain Research Reviews·Atsushi Takeda
Nov 13, 2003·European Journal of Pharmacology·Yoshikatsu Kanai, Matthias A Hediger
Jan 20, 2004·Glia·Nicholas J MaragakisJeffrey D Rothstein
Jan 30, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Giuseppe BattagliaValeria Bruno
Sep 29, 2004·Proceedings of the National Academy of Sciences of the United States of America·Nicola J BroadbentRobert E Clark
Oct 21, 2005·Neurology·I G McKeithUNKNOWN Consortium on DLB
Jan 5, 2007·Behavioral Neuroscience·Michael R HunsakerRaymond P Kesner
Oct 24, 2007·Experimental Neurology·Marie-Francoise Chesselet
Dec 7, 2007·Clinical Neuroscience Research·R Lee MosleyHoward E Gendelman
Jun 14, 2008·Schizophrenia Bulletin·Afonso C Silva, Nicholas A Bock
Apr 29, 2009·International Journal of Molecular Sciences·Katrin BeyerAurelio Ariza
Jul 17, 2009·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Haruhiko OdaKiyoshi Maeda
Feb 26, 2011·Cell Calcium·Laura TexidóCarlos Matute
Jul 8, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Youngshin LimVirginia M-Y Lee
Jan 10, 2012·Behavioural Brain Research·Ming-Hong HsiehFu-Ying Wu
May 2, 2012·Alzheimer's Research & Therapy·Samuel E Marsh, Mathew Blurton-Jones
Jun 1, 2012·British Journal of Pharmacology·Wojciech Danysz, Chris G Parsons
Apr 19, 2013·CNS Neuroscience & Therapeutics·Zaira EspositoAlessandro Martorana
Oct 9, 2013·ACS Chemical Neuroscience·Paolo RuzzaGianPietro Sechi
Nov 15, 2013·Journal of Neuropathology and Experimental Neurology·Martí Colom-CadenaAlberto Lleó

❮ Previous
Next ❯

Citations

Apr 12, 2019·Frontiers in Neuroscience·Ebrahim M YimerKald Beshir Tuem

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay

Software Mentioned

Image Pro Plus
MEMRI

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.